Biocryst pharmaceuticals inc
BCRX 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
BCRX 近期報酬表現
-
Biocryst pharmaceuticals inc
6.23%
同產業平均
1.02%
S&P500
與 BCRX 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
MOLN | Molecular partners ag (adr) | - | 2 分 | 2 分 | 1 分 | 1 分 | |
MLYS | Mineralys therapeutics inc | - | 3 分 | 2 分 | 2 分 | 1 分 | |
PRME | Prime medicine inc | - | 1 分 | 1 分 | 2 分 | 1 分 | |
BLUE | Bluebird bio inc | 3 分 | 1 分 | 2 分 | 2 分 | 1 分 | |
SNDX | Syndax pharmaceuticals inc | 3 分 | 3 分 | 2 分 | 3 分 | 1 分 |
- MOLN Molecular partners ag (adr)價值 -趨勢 2 分波段 2 分籌碼 1 分股利 1 分查看更多
BCRX 公司資訊
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.